Inhibrx, Inc. (NASDAQ:INBX) Short Interest Up 10.1% in December

Inhibrx, Inc. (NASDAQ:INBX - Get Free Report) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 1,200,000 shares, a growth of 10.1% from the November 30th total of 1,090,000 shares. Based on an average daily volume of 77,600 shares, the short-interest ratio is currently 15.5 days. Approximately 12.1% of the shares of the stock are sold short.

Insider Transactions at Inhibrx

In related news, Director Jon Faiz Kayyem acquired 69,686 shares of the firm's stock in a transaction on Tuesday, November 19th. The shares were purchased at an average price of $14.23 per share, with a total value of $991,631.78. Following the acquisition, the director now directly owns 51,093 shares in the company, valued at $727,053.39. The trade was a -374.80 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 22.20% of the company's stock.

Inhibrx Price Performance

Shares of INBX stock traded up $0.26 during trading hours on Tuesday, reaching $15.40. 42,174 shares of the company were exchanged, compared to its average volume of 127,666. Inhibrx has a fifty-two week low of $10.80 and a fifty-two week high of $18.95. The stock's fifty day moving average is $15.11 and its two-hundred day moving average is $14.64.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.